Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights
Avoid or reduce NVIDIA (NVDA) ahead of earnings if you’re uncomfortable with guidance risk; watch China-related sales and customer financing for signs of weakness.
Stay cautious on Nebius (NBIS): the speaker was explicitly bearish, though no price target or timing was provided.
Consider money-market funds for liquid, lower-volatility cash holdings; compare current yields and fees before choosing a fund.
Treat Eli Lilly (LLY) as a growth-sensitive investment: its valuation depends heavily on sustained GLP-1 growth, and the cited $1,200 value was only a scenario—not a firm target.
Detailed Analysis
NVIDIA (NVDA)
Shkreli said he would sell and would be “scared of holding” NVIDIA ahead of its earnings.
His central concern was that guidance could be weak if the company excludes Singapore sales—which he characterized as effectively Chinese sales—and if circular financing involving customers or partners fades.
He said the company could “kitchen sink” its results and outlook, potentially making the next quarter look especially poor. He also described the outcome as dependent in part on political decisions affecting chip sales to China.
NVIDIA shares moved sharply during the session, but the speaker’s focus was on earnings guidance rather than the day’s price fluctuations.
Takeaways
The discussion points to China-related revenue, customer financing, and forward guidance as key issues to monitor in NVIDIA’s earnings.
Shkreli’s explicit stance was bearish, but his comments also included uncertainty about political developments and the possibility of Jensen Huang returning to leadership. Treat the intraday price moves as context, not as a forecast.
Semiconductor and AI Infrastructure Stocks
The speaker described a broad selloff in chip and AI-related names, including AMD (AMD), Micron (MU), SanDisk (SNDK), Nebius (NBIS), Lumentum (LITE), Coherent (COHR), GE Vernova (GEV), Marvell (MRVL), and Intel (INTC).
He said AMD, Micron, SanDisk, Lumentum, and others were down during the session. These price moves were observations, not necessarily individual buy or sell recommendations.
He was specifically bearish on Nebius, calling it “dog.” He said Marvell’s deal was interesting but had no clear view on whether its shares would recover.
He said the compute-and-memory trend could be exciting, while also noting that AI infrastructure views can change frequently. He mentioned competition among AI-chip and accelerator companies, including Etched, SambaNova, MatX, Neurophos, Positron, and Groq; these are private companies or ventures rather than straightforward public-stock opportunities.
Takeaways
The transcript highlights a tension between potential long-term demand for compute and memory and near-term risks from weak guidance, financing concerns, and shifting AI infrastructure expectations.
The speaker’s comments were more negative on Nebius and uncertain on several other names. The discussion does not provide a specific valuation or price target for these stocks.
SpaceX and Space Stocks
Shkreli said he was “pretty bearish on space”, with the exception of space-related businesses tied to telecommunications.
He described SpaceX as exposed to cloud or “neocloud” activity through renting GPUs, and suggested that this was relevant to its share-price movement. SpaceX is a private company, so its shares are not generally available through public stock markets.
Takeaways
The speaker’s view was broadly cautious on space investments, while distinguishing telecommunications-related activity as a possible exception.
For private-market investors, the transcript raises GPU-rental and cloud exposure as a factor to investigate, but does not offer a specific valuation or recommendation for SpaceX.
Bitcoin (BTC)
Shkreli said he was “kind of bearish on Bitcoin.” He did not provide a price target, timeline, or specific reason for that view.
Takeaways
The transcript gives a bearish sentiment signal, but not enough detail to build a thesis or trading plan. No price target or catalyst was stated.
Eli Lilly (LLY)
Shkreli was not long Lilly and questioned whether its GLP-1 drug revenue could keep growing at a high rate.
He cited roughly $17.1 billion in GLP-related revenue for the prior quarter, up from about $16.2 billion. He also noted 36% revenue growth in that quarter and approximately $41 billion in net debt.
He discussed projected GLP revenue of about $65 billion and $80 billion for 2027, while questioning how durable the growth would be as the market matures and products face competition or eventual generic entry.
In one valuation scenario, he said an 8% discount rate implied a share value around $1,200. He framed the valuation as dependent on assumptions about GLP growth and future products, rather than as a firm price target.
He suggested the valuation would be more attractive if new drugs—including a drug name rendered unclearly in the transcript—became major sellers. He also noted uncertainty about future patent expirations and product mix.
Takeaways
The investment case discussed is highly dependent on how large and durable the GLP market becomes, and on Lilly’s ability to offset competition and future generic pressure.
Investors evaluating Lilly would need to test different growth and valuation assumptions. The speaker was skeptical, but his valuation discussion was scenario-based rather than a definitive forecast.
Moderna (MRNA) and BioNTech (BNTX)
Shkreli said Moderna had fallen from a recent high he recalled near $280 to around $215 during the session. He said he was not long Moderna.
When asked to compare Moderna with BioNTech, he said they were “very different companies” and did not give a clear preference between them.
Takeaways
The transcript is cautious on Moderna but provides no detailed investment thesis for either company.
The cited prices describe the session discussed; they are not price targets or current-market guidance.
CG Oncology (CGON)
Shkreli reacted positively to the company’s data on recurrence-free survival in non-muscle-invasive bladder cancer, calling it “nice data.”
He cited a ratio of 0.32, but did not explain the statistic in detail. He also observed that the stock had moved from around $100 to $80 after the data, and suggested the results may have been widely expected.
Takeaways
The speaker’s reaction to the clinical data was positive, but the transcript does not provide enough detail to independently assess the trial or its statistical significance.
The share-price move illustrates that promising data may already be reflected in expectations—or may fail to sustain a rally. The cited prices are session-specific, not targets.
Abivax (ABVX)
Shkreli said, “I think Abivax is a buy,” though he phrased it tentatively and did not explain the underlying thesis.
Takeaways
This was a brief, positive comment, not a developed recommendation. The transcript provides no valuation, catalyst, or risk assessment.
Other Public Companies Mentioned
Robinhood (HOOD): Shkreli noted that the stock had fallen substantially—roughly 50%, by his estimate—but did not give a view on whether it was a buy.
Opendoor (OPEN): He said he liked the CEO but was unsure what the company was doing and felt it was not doing much. This was a skeptical observation, not a formal rating.
Sarepta Therapeutics (SRPT): He said he still liked the company but called it speculative.
Zura Bio (ZURA): A viewer said they had lost their house on the stock; Shkreli responded dismissively. The exchange offers no substantive analysis of the company, but underscores the danger of concentrating personal finances in a speculative stock.
Marvell (MRVL): He called a deal interesting but said he had no idea whether the shares would recover.
Takeaways
These remarks are brief and do not establish a complete investment thesis. In particular, the transcript explicitly describes Sarepta as speculative and gives no buy case for Robinhood, Opendoor, or Zura Bio.
Money-Market Funds and Credit Risk
Shkreli said a money-market fund is “always a good play,” without specifying a product, yield, or time horizon.
He discussed credit-default-swap (CDS) spreads available through his platform and named distressed or higher-risk borrowers, including CoreWeave (CRWV), American Airlines (AAL), Walgreens (WBA), Goodyear (GT), Bausch Health (BHC), Unisys (UIS), Beazer Homes (BZH), and several sovereign issuers, including Argentina, Ecuador, Angola, Kenya, and Pakistan.
He said CoreWeave and Argentina had similar default probabilities according to the data he was viewing. He also mentioned Virgin Media Finance as already bankrupt.
Takeaways
The money-market comment reflects a preference for a relatively liquid, lower-volatility place to hold cash, but the transcript gives no yield comparison or specific recommendation.
The CDS discussion is a credit-risk signal, not a stock-picking endorsement. Elevated spreads can indicate that investors see greater risk of default; the transcript does not provide enough detail to assess any one issuer’s securities.
Investment Themes
Healthcare and biotech: Shkreli said healthcare can perform well during cyclical stress, while also discussing individual drug-development and clinical-data risks.
Compute and memory: He described this as a potentially exciting trend, but paired it with concerns about AI infrastructure spending, financing, and guidance.
AI investment risk: He questioned whether AI infrastructure expectations could weaken and said there may be problems if circular financing stops. He also noted that AI hardware competition could shift demand among GPUs and alternative accelerators.
Takeaways
The discussion suggests separating long-term themes from near-term company risks: a promising sector trend does not remove the importance of cash flows, financing, competition, and guidance.
The transcript provides no specific entry prices or portfolio allocations for these themes.
Ask about this postAnswers are grounded in this post's content.
Video Description
🔴 USE CODE: THESHKRELIPILL for 30% OFF! https://app.godelterminal.com/?via=theshkrelipill
► How This Stock’s Chart Predicts the Quantum Bubble’s Future | Ginkgo Bioworks DNA https://youtu.be/idEBQ6UrGPY
► I'm Making Money Losing on a Stock | Strategy and My 5 Positions https://youtu.be/XTiWc6ubsQw
► I'm Down 4 Million $. Trades Have To Go Against You | IonQ, Trading Synthetic Puts https://youtu.be/32oXhxVaIXE
► How I'm Trading LAES and IONQ on the Way Down https://youtu.be/0TIuLb4xWLM
📖 [𝗠𝗔𝗥𝗧𝗜𝗡'𝗦 𝗕𝗢𝗢𝗞 𝗥𝗘𝗖𝗢𝗠𝗠𝗘𝗡𝗗𝗔𝗧𝗜𝗢𝗡𝗦 𝗙𝗥𝗢𝗠 𝗛𝗜𝗦 𝗟𝗜𝗩𝗘𝗦𝗧𝗥𝗘𝗔𝗠𝗦]
𝗙𝗨𝗟𝗟 𝗟𝗜𝗦𝗧 👉 https://pastebin.com/XiG8KHd6
📖 𝐉𝐢𝐦 𝐂𝐨𝐥𝐥𝐢𝐧𝐬: 𝐆𝐨𝐨𝐝 𝐭𝐨 𝐆𝐫𝐞𝐚𝐭: 𝐖𝐡𝐲 𝐒𝐨𝐦𝐞 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐌𝐚𝐤𝐞 𝐭𝐡𝐞 𝐋𝐞𝐚𝐩
[BOOK] https://amzn.to/4nASn1y
[KINDLE] https://amzn.to/4mW16u7
[FREE AUDIO W/ FREE TRIAL] https://amzn.to/4ocpusC
📖 𝐑𝐨𝐛𝐞𝐫𝐭 𝐌 𝐏𝐢𝐫𝐬𝐢𝐠: 𝐙𝐞𝐧 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐀𝐫𝐭 𝐨𝐟 𝐌𝐨𝐭𝐨𝐫𝐜𝐲𝐜𝐥𝐞 𝐌𝐚𝐢𝐧𝐭𝐞𝐧𝐚𝐧𝐜𝐞: 𝐀𝐧 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 𝐢𝐧𝐭𝐨 𝐕𝐚𝐥𝐮𝐞𝐬
[BOOK] https://amzn.to/48R8Aer
[KINDLE] https://amzn.to/4oe9MNv
[FREE AUDIO W/ FREE TRIAL] https://amzn.to/48WgfZ1
📖 𝐁𝐫𝐲𝐚𝐧 𝐁𝐮𝐫𝐫𝐨𝐮𝐠𝐡: 𝐁𝐚𝐫𝐛𝐚𝐫𝐢𝐚𝐧𝐬 𝐚𝐭 𝐭𝐡𝐞 𝐆𝐚𝐭𝐞: 𝐓𝐡𝐞 𝐈𝐧𝐬𝐢𝐝𝐞 𝐒𝐭𝐨𝐫𝐲 𝐨𝐟 𝐀𝐦𝐞𝐫𝐢𝐜𝐚’𝐬 𝐌𝐨𝐬𝐭 𝐍𝐨𝐭𝐨𝐫𝐢𝐨𝐮𝐬 𝐂𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐓𝐚𝐤𝐞𝐨𝐯𝐞𝐫
[BOOK] https://amzn.to/4gZk9SR
[KINDLE] https://amzn.to/46Kkky9
[FREE AUDIO W/ FREE TRIAL] https://amzn.to/4gXeI6U
[𝗢𝗥𝗜𝗚𝗜𝗡𝗔𝗟 𝗩𝗜𝗗𝗘𝗢]
https://www.youtube.com/watch?v=p-uh4lUf2ws
[𝗧𝗜𝗠𝗘𝗦𝗧𝗔𝗠𝗣𝗦] | [💎] = tips, advice, gems
00:00 [💎] The Upcoming Earnings That Which Could Trigger a Massive Tech Selloff
01:31 Political Power Struggles Behind the Scenes at Nvidia (NVDA)
02:37 Why Q3 Guidance Is Going to Shock the Market
03:26 The Myth of Chips as National Security and the End of Circular Financing
04:53 Corporate Lawyers and the Sudden Ouster at Moderna (MRNA)
07:06 Robinhood (HOOD) Shares Getting Hammered by 50%
07:27 [💎] How Eli Lilly (LLY) Needs to Triple GLP Revenue to Justify Its Valuation
10:41 Why I Am Extremely Bearish on Bitcoin and Space Stocks
12:50 Will Mounjaro and Retatrutide Become the Best-Selling Drugs of All Time?
16:33 The Truth About Nvidia's (NVDA) Guidance and Circular Financing Risks
17:55 Comparing Micron (MU) and Competitors in the Memory and AI Infrastructure Race
21:40 Jensen Won't Be Back Yet
23:44 [💎] Exposing the Scam Behind Online Retail Trading Prop Firms
24:11 [💎] Who Really Makes Nvidia (NVDA) Chips
[𝗠𝗔𝗥𝗧𝗜𝗡'𝗦 𝗢𝗙𝗙𝗜𝗖𝗜𝗔𝗟 𝗬𝗢𝗨𝗧𝗨𝗕𝗘 𝗖𝗛𝗔𝗡𝗡𝗘𝗟𝗦]
🔴 𝗙𝘂𝗹𝗹 𝗟𝗶𝘃𝗲𝘀𝘁𝗿𝗲𝗮𝗺𝘀 𝗛𝗲𝗿𝗲: @realmartinshkreli
https://www.youtube.com/@realmartinshkreli/streams
🔴 𝗠𝗮𝗿𝘁𝗶𝗻'𝘀 𝗙𝗶𝗻𝗮𝗻𝗰𝗲 & 𝗖𝗵𝗲𝗺𝗶𝘀𝘁𝗿𝘆 𝗟𝗲𝘀𝘀𝗼𝗻𝘀 @mrmartinshkreli8223
https://www.youtube.com/@mrmartinshkreli8223/videos
[𝗦𝗢𝗖𝗜𝗔𝗟𝗦]
𝗦𝗵𝗸𝗿𝗲𝗹𝗶'𝘀 𝗦𝗼𝗰𝗶𝗮𝗹: https://linktr.ee/martinshkreli
𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗛𝗶𝘀 𝗦𝘁𝗿𝗲𝗮𝗺: https://streamlabs.com/martinshkreli2
𝗪𝗲𝗯𝘀𝗶𝘁𝗲: http://www.martinshkreli.com/
𝗚𝗶𝘁𝗵𝘂𝗯: https://github.com/martinshkreli
[𝗣𝗟𝗔𝗬𝗟𝗜𝗦𝗧𝗦]
https://www.youtube.com/@TheShkreliPill/playlists
[𝗙𝗜𝗡𝗔𝗡𝗖𝗘 𝗔𝗡𝗗 𝗜𝗡𝗩𝗘𝗦𝗧𝗜𝗡𝗚 𝗖𝗟𝗔𝗦𝗦 [𝟮𝟬𝟭𝟲] 𝗧𝗜𝗠𝗘𝗦𝗧𝗔𝗠𝗣𝗦 𝗔𝗡𝗗 𝗘𝗗𝗜𝗧𝗘𝗗]
https://www.youtube.com/playlist?list=PLBfupwmfhBrWnPtx_5Nm4OvhqmRXdD9AF
[𝗕𝗘𝗦𝗧 𝗢𝗙 𝗠𝗔𝗥𝗧𝗜𝗡 𝗦𝗛𝗞𝗥𝗘𝗟𝗜: 𝗜𝗱𝗲𝗮𝘀 & 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄𝘀]
https://www.youtube.com/watch?v=M2aRJ4ljm0o&list=PLBfupwmfhBrVjLr-lRNa_tDjVatMA9S9d&index=19
[𝗢𝗣𝗧𝗜𝗢𝗡𝗦 𝗔𝗡𝗗 𝗦𝗛𝗢𝗥𝗧𝗜𝗡𝗚 𝗦𝗧𝗥𝗔𝗧𝗘𝗚𝗜𝗘𝗦 | 𝗠𝗮𝗿𝘁𝗶𝗻 𝗦𝗵𝗸𝗿𝗲𝗹𝗶]
https://www.youtube.com/playlist?list=PLBfupwmfhBrUm2y3lLiKSN4FDmly5vipV
[𝗗𝗥𝗨𝗚 𝗗𝗜𝗦𝗖𝗢𝗩𝗘𝗥𝗬 𝗣𝗥𝗢𝗖𝗘𝗦𝗦 & 𝗣𝗔𝗧𝗘𝗡𝗧 𝗗𝗨𝗥𝗔𝗧𝗜𝗢𝗡𝗦]
https://www.youtube.com/playlist?list=PLBfupwmfhBrU5M3f2OZ2BhPnaQyGwnnYn
[𝗜𝗡𝗩𝗘𝗦𝗧𝗜𝗡𝗚 & 𝗙𝗜𝗡𝗔𝗡𝗖𝗜𝗔𝗟 𝗟𝗘𝗦𝗦𝗢𝗡𝗦]
https://www.youtube.com/watch?v=yZMHBcQncgk&list=PLBfupwmfhBrXbXbKHdmk9nzjnO77Ok5qn&index=9
[𝗧𝗵𝗲 𝗙𝗧𝗫 / 𝗖𝗿𝘆𝗽𝘁𝗼 𝗖𝗿𝗮𝘀𝗵 𝗘𝗿𝗮 [𝟮𝟬𝟮𝟮] | 𝗠𝗮𝗿𝘁𝗶𝗻 𝗦𝗵𝗸𝗿𝗲𝗹𝗶]
https://www.youtube.com/watch?v=jklylG7pBF0&list=PLBfupwmfhBrWq8DwWFcnzKPf42WJtJ3Kd&index=4
[ ! ] The videos on my YouTube channel include material from Martin Shkreli’s livestreams. The use of the video material is authorized by Martin Shkreli
Any video material that appears identically in uploads from other YouTube channels is purely coincidental. I have no control over or ownership of such reuploads and am not aware of their relationship with the original creator.
[𝗔𝗙𝗙𝗜𝗟𝗜𝗔𝗧𝗘 𝗟𝗜𝗡𝗞 𝗗𝗜𝗦𝗖𝗟𝗔𝗜𝗠𝗘𝗥]
Amazon links above include affiliate commission or referrals.
I'm part of an affiliate network and I receive compensation from partnering website.
By purchasing product through this link you help supporting this channel.